Corvus Pharmaceuticals Suspends $100M ATM Stock Offering Filed August 6, 2024; No ATM Shares Had Been Sold And All $100M Of The ATM Shares Remained Available For Sale Pursuant To The Sale Agreement

On January 20, 2026, in connection with the proposed registered underwritten public offering, Corvus Pharmaceuticals, Inc. (the "Company") notified Jefferies LLC ("Jefferies") that it has suspended the offering of any shares of its common stock, par value $0.0001 per share, pursuant to the prospectus supplement filed with the Securities and Exchange Commission (the "SEC") on August 6, 2024 under the Company's shelf Registration Statement on Form S-3 (File No. 333-281318) which became effective on August 15, 2024, relating to the Open Market Sale AgreementSM, dated August 6, 2024 (the "Sale Agreement"), by and between the Company and Jefferies covering the sale of up to $100 million shares (the "ATM Shares") of its common stock. Prior to suspension, no ATM Shares had been sold and all $100 million of the ATM Shares remained available for sale pursuant to the Sale Agreement. The Company will not make any sales of common stock pursuant to the Sale Agreement unless and until a new prospectus supplement or registration statement is filed with the SEC; however, the Sale Agreement remains in full force and effect.